Renaissance Technologies LLC Sells 370,637 Shares of Chimerix, Inc. (NASDAQ:CMRX)

Renaissance Technologies LLC cut its position in Chimerix, Inc. (NASDAQ:CMRX) by 20.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,483,178 shares of the biopharmaceutical company’s stock after selling 370,637 shares during the quarter. Renaissance Technologies LLC owned 1.65% of Chimerix worth $1,299,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of CMRX. Marquette Asset Management LLC raised its position in Chimerix by 24.3% in the first quarter. Marquette Asset Management LLC now owns 116,009 shares of the biopharmaceutical company’s stock valued at $123,000 after purchasing an additional 22,709 shares during the last quarter. Koshinski Asset Management Inc. bought a new position in Chimerix in the first quarter valued at about $42,000. Finally, Acadian Asset Management LLC raised its position in Chimerix by 15.5% in the first quarter. Acadian Asset Management LLC now owns 2,174,813 shares of the biopharmaceutical company’s stock valued at $2,304,000 after purchasing an additional 291,981 shares during the last quarter. 45.42% of the stock is currently owned by institutional investors.

Chimerix Stock Performance

Shares of Chimerix stock opened at $0.92 on Friday. Chimerix, Inc. has a 52 week low of $0.75 and a 52 week high of $1.30. The stock has a 50 day moving average price of $0.90 and a two-hundred day moving average price of $0.92. The stock has a market capitalization of $82.12 million, a PE ratio of -0.99 and a beta of 1.12.

Chimerix (NASDAQ:CMRX) last announced its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.23) EPS for the quarter, meeting analysts’ consensus estimates of ($0.23). Chimerix had a negative return on equity of 46.35% and a negative net margin of 25,337.96%. The firm had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $1.26 million. During the same quarter last year, the firm posted ($0.21) earnings per share. Research analysts forecast that Chimerix, Inc. will post -0.86 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on CMRX shares. StockNews.com upgraded Chimerix from a “sell” rating to a “hold” rating in a research report on Wednesday, August 21st. HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Chimerix in a research report on Wednesday, August 14th. Finally, Wedbush restated an “outperform” rating and set a $6.00 price objective on shares of Chimerix in a research report on Tuesday, August 13th.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.